INCR_OUT_1 [2025-04-14 11:48:24 -0400] 3406 Bytes | 925 tokens | Cum: 925 tkns (11.56% of 8k)
==========================================================================

Alright, let’s light it up, because it's 11:48:23 AM on Mon Apr 14, 2025 -0400, and I'm charging into Intercure (INCR), popping from 1.2360 to 1.2700. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Intercure (INCR)
IPO: 2019-01-01 (6 Years Ago)
Market Cap: $58,293,112
Shares Outstanding: 45,770,000
Exchange: XNAS
Description: Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. The products are distributed to hospitals, pharmacies, research, and government organizations. The company has two segments namely: Cannabis segment and Biomed segment, out of which it derives maximum revenue from Cannabis segment.

Here’s the first list of news for Intercure:

C1 - Feb-12-25 06:35PM - InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak
C2 - Dec-20-24 08:32AM - InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility
C3 - Sep-01-24 06:37PM - Weekly Roundup on the Cannabis Sector & Psychedelic Sector
C4 - Aug-29-24 06:03PM - InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
C5 - Aug-28-24 08:54AM - InterCure Announces Expansion of its Strategic partnership with Cookies to Germany
C6 - May-22-24 06:45AM - InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference
C7 - May-01-24 08:27AM - InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million
C8 - Apr-01-24 09:09AM - InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: Intercure (INCR).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
At the end, you'll be prompted to return these data pairs:

1) BRIEF_SUMMARY[] -- Write a brief summary
2) MARKET_SCORE[] -- Assign a Market Score
3) PRICE_TARGET[] -- Set a price target
4) AI_RPT_HEADLINE[] -- Generate a headline for the article
5) SQUEEZE_POTENTIAL[] -- Potential for this stock to become an active short squeeze play
6) TAGS[] -- 1 to 4 words for SEO tags
7) STOCK_TYPE[] -- Describe the type of investor style suited to this stock
8) PRIMARY_CATALYST[] -- What you believe caused this stock to move today
9) SENTIMENT[] -- Mkt sentiment of the opportunity
10) IMPROVEMENT_SUGGESTION[] -- What can we do better
11) ETHICAL_RATING[] -- Rate alignment with long-term shareholder interests

Restrict the next response to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

INCR_OUT_3 [2025-04-14 11:48:25 -0400] 473 Bytes | 128 tokens | Cum: 1055 tkns (13.19% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-25T06:00:24Z - InterCure (NASDAQ:INCR) Stock Price Down 3.4% - Time to Sell?...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

INCR_OUT_5 [2025-04-14 11:48:26 -0400] 1098 Bytes | 338 tokens | Cum: 1395 tkns (17.44% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**InterCure (NASDAQ:INCR) Stock Price Down 3.4% - Time to Sell?**Date: 2025-03-25Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/intercure-nasdaqincr-stock-price-down-34-time-to-sell-2025-03-25/InterCure Ltd. (NASDAQ:INCR - Get Free Report)'s share price fell 3.4% during mid-day trading on Monday . The stock traded as low as $1.43 and last traded at $1.44. 37,166 shares traded hands during mid-day trading, a decline of 6% from the average session volume of 39,383 shares. The stock had previously closed at $1.49.

The company has a quick ratio of 1.15, a current ratio of 1.78 and a debt-to-equity ratio of 0.15. The firm's 50-day moving average price is $1.63 and its 200-day moving average price is $1.64.

Several hedge funds have recently added to or reduced their stakes in the stock. Moore Capital Management

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

INCR_OUT_7 [2025-04-14 11:48:26 -0400] 891 Bytes | 279 tokens | Cum: 1676 tkns (20.95% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-08-29T22:03:00Z - InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million
B2 - 2024-05-24T20:13:30Z - Asset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQ
B3 - 2024-02-13T21:46:00Z - InterCure Provides an Update Regarding Nir Oz Facility
B4 - 2024-01-31T14:27:00Z - InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
B5 - 2023-10-31T20:39:00Z - InterCure Wins Cannolam Arbitration Proceeding
B6 - 2023-10-17T21:04:00Z - InterCure Provides an Update Regarding the Security Situation in Israel

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

INCR_OUT_9 [2025-04-14 11:48:30 -0400] 910 Bytes | 258 tokens | Cum: 1936 tkns (24.20% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/08/29/2938189/0/en/InterCure-Announces-First-Half-of-2024-Results-Revenue-of-NIS-126-million-and-Adjusted-EBITDA-of-NIS-21-million.htmlInterCure reported revenue of NIS 126 million and adjusted EBITDA of NIS 21 million for the first half of 2024. The company's southern facility was affected by a terrorist attack and the war in Gaza, but it is entitled to compensation from the Israeli authorities. InterCure plans to expand its partnership with Cookies and launch products in Germany and the UK.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

INCR_OUT_11 [2025-04-14 11:48:30 -0400] 238 Bytes | 59 tokens | Cum: 2092 tkns (26.15% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

INCR_OUT_13 [2025-04-14 11:48:37 -0400] 5694 Bytes | 1513 tokens | Cum: 3607 tkns (45.09% of 8k)
==========================================================================

This is our set of metrics for Intercure.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-----------------------+
| Volume: 11,495 | Perf Month: -21.60% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 20.83K | Perf Quarter: -22.08% | Short Float: 0.13% | ROE: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 1.58 | Index: - | Short Ratio: 1.64 | ROI: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 32.21 | Market Cap: 59.90M | Short Interest: 0.03M | Sales Surprise: 0.28% |
+--------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.07 | Shs Outstand: 45.57M | Beta: 1.18 | EPS Surprise: 51.38% |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA20: -7.91% | Shs Float: 27.16M | Sales Q/Q: -1.38% | P/E: - |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -16.79% | Inst Own: 8.65% | Sales past 5Y: - | Earnings: Nov 12 |
+--------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -27.19% | Insider Own: 42.42% | Employees: - | |
+--------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: -3.05% | Insider Trans: 0.00% | Debt/Eq: - | |
+--------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Intercure officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 5418970000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': 71221000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.27
Average Volume: 18373.71
30-Day High: 1.6
30-Day Low: 1.22

[Detailed Financials: FY 2017]
- Total Assets: $7,285,867,000.0
- Total Liabilities: $4,263,288,000.0
- Total Equity: $3,022,579,000.0
- Current Assets: $1,422,179,000.0
- Current Liabilities: $1,159,562,000.0

[Income Statement: FY 2017]
- Revenue: $2,672,064,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.85

[Cash Flow Statement: FY 2017]
- Net Cash Flow: $218,791,000.0

[Detailed Financials: Q3 2017]
- Total Assets: $7,296,954,000.0
- Total Liabilities: $4,270,645,000.0
- Total Equity: $3,026,309,000.0
- Current Assets: $1,362,802,000.0
- Current Liabilities: $1,073,610,000.0

[Income Statement: Q3 2017]
- Revenue: $592,207,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.7

[Cash Flow Statement: Q3 2017]
- Net Cash Flow: $134,673,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Intercure (INCR).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Intercure.

2) MARKET_SCORE[]
This conversation was initiated because INCR is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for INCR.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, INCR could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect INCR to increase 50% from its current price of $1.27, say: PRICE_TARGET[1.91]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Intercure.

11) ETHICAL_RATING[]
Rate Intercure’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

INCR_IN_15 [2025-04-14 11:48:37 -0400] 126 Bytes | 29 tokens | Cum: 3818 tkns (47.73% of 8k)
==========================================================================

====================================
[2025-04-14 11:48:37] # Analysis Completed
Elapsed Time: 14.10 seconds